Epidemiology of keratinocyte carcinomas after organ transplantation.
M M Madeleine, N S Patel, E I Plasmeijer...
https://pubmed.ncbi.nlm.nih.gov/28994104/Actively Recruiting
Led by Falo, Louis, MD · Updated on 2026-04-09
48
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are evaluating a new experimental treatment for cutaneous squamous cell carcinoma cSCC, a type of skin cancer, using small adhesive patches called microneedle arrays MNA. These patches contain tiny needles loaded with very low doses of doxorubicin, a chemotherapy drug. The study aims to test the safety and effectiveness of these patches in both patients with normal immune systems and those who are immunosuppressed due to organ transplants. The treatment involves applying the MNA-Doxorubicin patches directly to the cancerous skin lesion for 20 minutes once a week over four weeks. After these applications, there is a rest period followed by a final follow-up visit between weeks 5 and 8. At the final visit, any remaining cancerous tissue will be surgically removed using standard care procedures to ensure complete treatment. Participants will undergo regular evaluations including skin assessments where the patches are applied, blood tests, and tissue analyses to monitor treatment responses and safety. Researchers will measure adverse events, tumor response, immune system activity, and tumor clearance. The entire study period spans from screening to final follow-up at around 8 weeks, with ongoing safety monitoring throughout.
CONDITIONS
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
C
Charity L Ruhl, LPN
N
Nicolena Verardi
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Falo, Louis, MD
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Microneedle Array with Doxorubicin Patch | Surgical Excision (Standard of Care) |
|---|---|---|
| What it is | A microneedle array patch pre-loaded with doxorubicin is applied directly to the surface of a primary cSCC tumor. | A surgical procedure in which the entire primary cSCC lesion is removed with clinical margins and confirmed by histology. |
| Role in the trial | Studied as an experimental, local non-surgical treatment for resectable stage I-III cSCC. | Serves as the established standard for initial treatment of localized resectable cSCC. |
| Primary use | Designed to deliver chemotherapy directly into the tumor with the goal of local tumor control. | Removes both visible tumor and surrounding tissue margins, aiming to cure localized cSCC and prevent recurrence. |
| How it is given or performed | The patch is placed on the selected cSCC lesion for 20 minutes per session and repeated once a week for four weeks. | Performed as an outpatient surgical procedure under appropriate anesthesia with histological confirmation of negative margins. |
| Evidence status | Under investigation in ongoing early phase clinical trial; results not yet established. | Guideline-supported as the mainstay for resectable cSCC, with extensive evidence for effectiveness in local tumor control and long-term outcomes. |
| Important limitations | Limited to lesions without high-risk pathological features. Safety and clinical benefit have not yet been established in the studied patient group. | Requires a surgical procedure which may cause scarring, and some anatomic sites or aggressive tumors may need more extensive approaches. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks (weeks 0 to 3)
Participants receive 4 weekly applications of the Microneedle Array Doxorubicin patch. Each application involves placing the patch on the tumor for 20 minutes to deliver chemotherapy directly to the cutaneous squamous cell carcinoma lesion.
4 weekly visits (in-person)
Duration - 4 weeks (weeks 5 to 8)
After a rest week, participants have follow-up visits to assess treatment response and safety. At the final visit, the remaining tumor lesion is surgically removed using standard of care to ensure clear tissue margins.
Approximately 2 visits (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
M M Madeleine, N S Patel, E I Plasmeijer...
https://pubmed.ncbi.nlm.nih.gov/28994104/Vishal Madan, John T Lear, Rolf-Markus Szeimies
https://pubmed.ncbi.nlm.nih.gov/20171403/Sharifeh Farasat, Siegrid S Yu, Victor A Neel...
https://pubmed.ncbi.nlm.nih.gov/21255868/Andrew Freeman, Jennifer A Bridge, Pirashanthini Maruthayanar...
https://pubmed.ncbi.nlm.nih.gov/25340823/A Hanlon, O R Colegio
https://pubmed.ncbi.nlm.nih.gov/24612476/Pritesh S Karia, Jiali Han, Chrysalyne D Schmults
https://pubmed.ncbi.nlm.nih.gov/23375456/Yvonne Y Li, Glenn J Hanna, Alvaro C Laga...
https://pubmed.ncbi.nlm.nih.gov/25589618/Falo, Louis, MD
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor